In this article, we will examine the 15 Best Multibagger Stocks to Invest in Right Now.
Just as a single diamond can outshine a handful of pebbles, a well-chosen multibagger can transform an ordinary portfolio into an extraordinary one. By definition, multibagger stocks are companies that deliver returns far exceeding the broader market, often doubling, tripling, or multiplying their value many times over.
The term was popularized by legendary fund manager Peter Lynch, who coined expressions like “tenbagger” to describe stocks that appreciate tenfold. Lynch believed that investors could spot good companies by observing their daily lives, at the mall, in restaurants, or at work. He argued that this kind of awareness often gave individual investors an advantage over Wall Street, which usually recognized these trends only after the fact.
READ ALSO: 12 Overlooked Large-Cap Stocks with Low Multiples and 10 Best Stocks for a 20 Year Long-Term Stock Portfolio.
The essence of finding multibaggers lies in spotting companies with sustainable growth drivers, strong competitive positions, and the ability to scale. These are businesses that tap into long-term trends, be it technology adoption, consumer demand shifts, or new industrial cycles, and convert that momentum into consistent earnings growth.
The market is already ripe for further gains, with expectations running high on an upcoming rate cut. In a recent CNBC interview, Gabriela Santos, Americas Chief Market Strategist at JPMorgan Asset Management, stated that U.S. equities are expected to continue setting new highs through the rest of the year. While many analysts and investors, including Ed Yardeni of Yardeni Research, have set targets of 6,600 for the S&P 500, Mary Ann Bartels, Chief Investment Strategist at Sanctuary Wealth, believes the index could reach 7,000 by year’s end.
In these scenarios, finding the next multibagger is never easy, but the payoff can be significant. One winning stock can offset several laggards, making multibaggers a valuable part of any long-term portfolio.
With those insights in mind, let’s now explore the 15 best multibagger stocks to invest in right now.
vichie81/Shutterstock.com
Our Methodology
To compile our list of the best multibagger stocks, we first screened U.S.-listed companies with a market capitalization above $500 million. From this group, we shortlisted stocks that had delivered at least 100% returns over the past year and offered a further potential upside of 40% or more. We then ranked the top 15 stocks in ascending order of their estimated upside. Additionally, we also included data on hedge fund holdings in these companies as of Q2 2025 from Insider Monkey’s database to provide further insight into investor interest.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Note: All pricing data is as of market close on September 4, 2025.
15 Best Multibagger Stocks to Invest in Right Now
15. Scholar Rock Holding Corp. (NASDAQ:SRRK)
Market Cap: $3.1 Billion
Price Return over 1-Year: 270%
Potential Upside: 57%
Number of Hedge Fund Holders: 44
Scholar Rock Holding Corp. (NASDAQ:SRRK) is one of the best multibagger stocks to invest in right now. The company’s stock’s performance was largely supported by optimism around its lead drug candidate, apitegromab. The stock surged nearly sixfold in 2024, but as the company approaches a potential U.S. market launch in Q3 2025, volatility has increased. Shares are down approximately 25% year-to-date, although market sentiment remains highly positive, with a consensus Buy rating.
Why is apitegromab viewed as a potential game changer? Scholar Rock Holding Corp. (NASDAQ:SRRK) highlights that it is the first and only muscle-targeted therapy to show clinically meaningful and statistically significant functional improvement in SMA, and the only anti-myostatin therapy to demonstrate such results in a pivotal Phase 3 trial. Scholar Rock Holding Corp. (NASDAQ:SRRK) estimates the global market opportunity for apitegromab in SMA could exceed $2 billion, highlighting its strong commercial potential.
Recent analyst commentary suggests that bullish expectations for Scholar Rock Holding Corp. (NASDAQ:SRRK) are likely to continue. On August 21, Jefferies analyst Amy Li initiated coverage on the stock with a Buy rating and a $50 price target. Li views apitegromab, the company’s lead drug candidate, as a strong commercial opportunity in spinal muscular atrophy (SMA), arguing that an FDA approval covering patients aged two and older across SMA types 1-4 would substantially expand the drug’s addressable market.
The analyst noted that the September 22 PDUFA date could face a modest delay into the first quarter due to procedural issues flagged during an FDA site inspection. However, she does not believe this will affect the likelihood of approval. Li modeled risk-adjusted peak sales of $1.8 billion for apitegromab, with a 90% probability of success in patients over two years of age and 50% for those under two.
She also highlighted the longer-term potential for apitegromab and pipeline candidate SRK-439 in other neuromuscular conditions, including Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), as well as possible applications in obesity through external partnerships.
Scholar Rock Holding Corp. (NASDAQ:SRRK) is a late-stage biopharmaceutical company focused on developing therapies for spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases.
14. Archer Aviation Inc. (NYSE:ACHR)
Market Cap: $5.3 Billion
Price Return over 1-Year: 152%
Potential Upside: 59%
Number of Hedge Fund Holders: 35
Archer Aviation Inc. (NYSE:ACHR) is one of the best multibagger stocks to invest in right now. With returns already exceeding 150% in the last year, the company is often cited as a potential multibagger in the emerging urban air mobility market. The company is developing eVTOL (electric vertical takeoff and landing) aircraft designed for urban air taxi services.
Six of its flagship Midnight aircraft are in production, with three currently in final assembly. Archer raised $850 million in funding in Q2 2025, bringing its cash reserves to a solid $1.7 billion.
On August 27, short seller Grizzly Research released a report on Archer Aviation Inc. (NYSE:ACHR), drawing parallels to other troubled start-ups and questioning the credibility of its $6 billion order book, the design of its Midnight aircraft, and the pace of production ramp-up at its Georgia facility. The note also raised doubts about the durability of some order commitments and highlighted concerns around recent marketing demonstrations.
Archer Aviation Inc. (NYSE:ACHR) has not yet commented, and Wall Street analysts have not released updated views, while the stock showed little immediate reaction.
Earlier, on August 13, Canaccord Genuity’s Austin Moeller maintained a Buy rating with a $13 price target after Q2 results. While acknowledging a sizable adjusted EBITDA loss, Moeller pointed to progress in scaling Midnight aircraft production across California and Georgia, and highlighted Archer Aviation Inc.’s (NYSE:ACHR) strengthened balance sheet following the capital raise. He also noted the company’s advancement in FAA certification, where it is among a select group in the final phase, as a critical step toward commercialization.
These differing perspectives underline the debate surrounding Archer Aviation Inc. (NYSE:ACHR). The short-seller’s report highlights questions around execution and order strength, while analyst views point to Archer’s funding base, progress with certification, and potential growth ahead. There could be volatility in the near term, but with substantial upside if the company is able to deliver on its key operational goals.
Archer Aviation Inc. (NYSE:ACHR) is a U.S.-based aerospace company developing electric vertical take-off and landing (eVTOL) aircraft for urban air mobility.
13. Innodata Inc. (NASDAQ:INOD)
Market Cap: $1.3 Billion
Price Return over 1-Year: 166%
Potential Upside: 61%
Number of Hedge Fund Holders: 16
Innodata Inc. (NASDAQ:INOD) is one of the best multibagger stocks to invest in right now. Its share price performance has been quite volatile, with year-to-date gains of only 4%, which means that the 1-year return of 166% mainly came in the latter part of 2024.
nodata Inc. (NASDAQ:INOD) provides AI training data, content digitization, and analytics solutions to technology, media, and financial firms. As these and similar industries are experiencing rapid digital transformation, the company’s specialized solutions position it well for this upcoming growth opportunities. Although the stock carries volatility due to small-cap exposure, its alignment with the high-growth AI ecosystem should offer higher return potential if execution remains consistent.
Despite the volatility, Innodata Inc. (NASDAQ:INOD) remains a consensus Buy, and the consensus price target indicates over 60% upside. Following the release of the last quarterly results on July 31, all analysts covering the company reiterated their Buy ratings, including Allen Klee from Maxim Group, who has a price target of $75.
Klee highlighted that Q2 results showed 79% year-over-year revenue growth, driven entirely by organic demand. Adjusted EBITDA has improved as well despite reinvestment, which highlights disciplined cost control. Thus, he believed that with no debt, strong cash flow, rising AI-related opportunities, and higher 2025 revenue guidance, Innodata Inc. (NASDAQ:INOD) remains well-positioned for sustained growth.
The day after the results, the stock corrected by 18%, and since Klee’s update, it has further corrected by 8%.
Innodata Inc. (NASDAQ:INOD) is a data engineering and AI services company that provides digital transformation solutions to enterprises and large technology companies.
12. Sezzle Inc. (NASDAQ:SEZL)
Market Cap: $2.8 Billion
Price Return over 1-Year: 279%
Potential Upside: 61%
Number of Hedge Fund Holders: 30
Sezzle Inc. (NASDAQ:SEZL) is one of the best multibagger stocks to invest in right now. The company operates in the fast-expanding “Buy Now, Pay Later” (BNPL) market, offering flexible payment solutions that benefit both merchants and consumers.
The company has substantial growth opportunities ahead. Worldpay, in its Global Payments Report 2025, forecasts that the global BNPL online value will grow at a 9% CAGR through 2030, reaching approximately $580 billion, up from $342 billion in 2024. Sezzle’s consumer-focused features, including Sezzle Up, which is now adopted by over 2.9 million users, set it apart from its peers by linking installment payments with credit-building.
In Q2 2025, the company reported $927 million in Gross Merchandise Volume (GMV), up 74% year-over-year, while total revenue grew 76.4% to $98.7 million. Strong operating discipline continues to show in financials, as adjusted net income rose 92% and adjusted EBITDA margin improved by 550 basis points year-over-year to 38.4%.
Despite a strong set of results, the stock declined by around 34% as management indicated a slowdown in growth and reiterated its guidance from Q1 2025, which disappointed investors. The stock is still up 100% year-to-date.
Analysts seemed to have maintained their conviction despite the uncertainty over growth. Following the results on August 8, B. Riley Financial analyst Hal Goetsch raised his price target from $101 to $111 and kept his Buy rating. Moreover, the analyst believed that the stock was attractively valued.
Sezzle Inc. (NASDAQ:SEZL) is a U.S.-based financial technology company specializing in BNPL solutions. Its platform enables consumers to split purchases into interest-free installments, while helping merchants increase sales and customer engagement.
11. Amprius Technologies Inc. (NYSE:AMPX)
Market Cap: $841 Million
Price Return over 1-Year: 662%
Potential Upside: 71%
Number of Hedge Fund Holders: 11
Amprius Technologies Inc. (NYSE:AMPX) is one of the best multibagger stocks to invest in right now. Amprius’ investment case rests on the company’s silicon nanowire anode, which enables the use of a 100% silicon anode, a technology that was previously considered unattainable in battery design. This breakthrough delivers energy densities of up to 500 watt-hours per kilogram, which far surpass those of conventional graphite batteries.
Its products have several other advantages that could drive outsized growth as demand for next-generation batteries accelerates.
On September 3, Oppenheimer analyst Colin Rusch reiterated a Buy rating on Amprius Technologies Inc. (NYSE:AMPX) with an unchanged price target of $17, implying a potential upside of over 135%.
This update follows Amprius Technologies Inc.’s (NYSE:AMPX) presentation at ‘The Gateway Conference 2025’, which was organized by Gateway Group during September 3-4. The company highlighted its ability to deliver superior energy and power density compared to conventional batteries, and also announced plans to introduce the enhanced SiCore platform in 2025.
Amprius Technologies Inc.’s (NYSE:AMPX) management said that they target markets where performance outweighs cost, such as aviation, defense, and light electric vehicles. Their clients include Airbus and the U.S. military, with recent momentum supported by a $15 million order from Nordic Wing, a European drone manufacturing company. Its contract manufacturing in Asia provides nearly 2 gigawatts of capacity, while plans for a U.S. partnership are advancing.
Amprius Technologies Inc. (NYSE:AMPX) is a developer and manufacturer of high-energy-density and high-power-density silicon-anode lithium-ion batteries.
10. Solaris Energy Infrastructure Inc. (NYSE:SEI)
Market Cap: $1.8 Billion
Price Return over 1-Year: 125%
Potential Upside: 74%
Number of Hedge Fund Holders: 38
Solaris Energy Infrastructure Inc. (NYSE:SEI) is one of the best multibagger stocks to invest in right now. On September 3, Barclays analyst David Anderson reiterated a Buy rating on Solaris Energy Infrastructure (SEI) with a $44 price target.
This stance by the analyst follows his July 28 decision to lift the target from $39 after the company delivered strong Q2 results and raised Q3 EBITDA guidance.
Anderson described the quarter as impressive, noting that the bigger takeaway lies in growing recognition of a looming power shortage. He argued that distributed power solutions remain one of the most effective ways to participate in the broader equipment cycle, positioning Solaris as a beneficiary of this structural shift.
The reaffirmed rating and target reflect confidence in both near-term execution and longer-term demand tailwinds, as investors increasingly focus on companies leveraged to distributed energy infrastructure.
Since Anderson’s July update to raise the price target, Solaris Energy Infrastructure Inc.’s (NYSE:SEI) stock has witnessed greater volatility and declined by around 17%. However, the consensus 12-month median price target still reflects a substantial 74% potential upside.
Solaris Energy Infrastructure Inc. (NYSE:SEI) develops and operates distributed energy solutions, including power generation and storage systems.
9. Strategy Inc (NASDAQ:MSTR)
Market Cap: $91.7 Billion
Price Return over 1-Year: 162%
Potential Upside: 82%
Number of Hedge Fund Holders: 45
Strategy Inc. (NASDAQ:MSTR) is one of the best multibagger stocks to invest in right now. The company positions itself as the world’s largest Bitcoin Treasury Company, a strategy shaped by CEO Michael Saylor’s view that bitcoin will replace gold as a non-governmental store of value. As of the end of July, the company held 628,791 bitcoins on its balance sheet, valued at about $70 billion at current prices.
Given the size of the company’s bitcoin exposure, the stock’s outlook is closely tied to movements in the cryptocurrency market. Reflecting that relationship, Lance Vitanza, an analyst from TD Cowen, reaffirmed a Buy rating on Strategy Inc. (NASDAQ:MSTR) on September 2. He also lowered his price target to $640 from $680. The revision reflects near-term pressures tied to bitcoin prices and broader capital market conditions.
The analyst highlighted that, during the week before his note, Strategy Inc. (NASDAQ:MSTR) purchased 4,048 bitcoins for $449.3 million, continuing its practice of raising equity to fund purchases. Vitanza said the strategy may draw skepticism, but noted that management is moving to take advantage of what many investors see as a temporary dip in bitcoin. He added that issuing stock to expand holdings reflects the company’s firm belief in bitcoin’s long-term place in global finance.
While the adjusted target acknowledges near-term volatility, the Buy rating reflects confidence in management’s consistent strategy of using balance sheet flexibility to grow exposure to digital assets.
Strategy Inc. (NASDAQ:MSTR), formerly known as MicroStrategy, is a technology company that calls itself the world’s first and largest Bitcoin Treasury Company. The company has substantial Bitcoin holdings, which form a core part of its corporate strategy. Additionally, its software platform provides enterprise analytics and data visualization solutions.
8. Precigen Inc. (NASDAQ:PGEN)
Market Cap: $1.3 Billion
Price Return over 1-Year: 370%
Potential Upside: 85%
Number of Hedge Fund Holders: 16
Precigen Inc. (NASDAQ:PGEN) is one of the best multibagger stocks to invest in right now. Among the company’s proprietary therapeutic platforms, its UltraCAR-T platform offers a differentiated approach to CAR-T treatment, aiming for faster manufacturing and potentially improved safety profiles. The company has multiple candidates progressing through clinical trials, which are being used to build a robust pipeline that addresses significant unmet medical needs.
Precigen Inc.’s (NASDAQ:PGEN) stock is up over 300% year-to-date. Its share price has doubled since mid-August after the successful FDA approval of its Papzimeos therapy, which is the first and only approved treatment for adults with recurrent respiratory papillomatosis.
The approval was seen as highly favourable by the street. Following the news, analysts from JPMorgan had upgraded the stock to Neutral from Underweight, citing the removal of a major overhang. Analysts from Cantor Fitzgerald and H.C. Wainwright had also reiterated their Buy ratings.
For H.C. Wainwright’s Swayampakula Ramakanth, the approval came earlier than expected and covers a broad indication in recurrent respiratory papillomatosis, targeting roughly 27,000 U.S. adults. With Q4 2025 sales projected at $15 million and a focused launch strategy, Ramakanth sees meaningful commercial potential despite regulatory and execution risks.
Precigen Inc. (NASDAQ:PGEN) is a biopharmaceutical company that develops gene and cellular therapies, with a focus on immuno-oncology, autoimmune disorders, and infectious diseases.
7. Aeva Technologies Inc. (NASDAQ:AEVA)
Market Cap: $750 Million
Price Return over 1-Year: 425%
Potential Upside: 87%
Number of Hedge Fund Holders: 19
Aeva Technologies Inc. (NASDAQ:AEVA) is one of the best multibagger stocks to invest in right now. The company develops next-generation 4D-LiDAR sensors for autonomous driving and industrial applications. It utilizes a technology known as frequency-modulated continuous wave (FMCW) technology, which enables it to provide superior range, velocity detection, and resistance to interference compared to traditional LiDAR systems.
Its addressable market spans $80 billion across mobility, defense, robotics, and consumer applications. With $500 million invested in R&D and over 245 granted patents, Aeva Technologies Inc. (NASDAQ:AEVA) has established a defensible technology moat.
Aeva Technologies Inc. (NASDAQ:AEVA) is already engaging with top automotive OEMs, heavy-duty trucking leaders, and industrial automation partners, supported by collaborations with manufacturing specialists like Jabil and Tower Semiconductor. This strong roster of partners is expected to help the company bring 4D-LiDAR to mass scale.
The majority of analysts are optimistic on Aeva Technologies Inc. (NASDAQ:AEVA), with the latest being George Gianarikas from Canaccord Genuity, who reiterated his Buy rating and raised his price target from $16 to $24 in early August. The company’s stock has surged nearly 180% this year, justifying the positive views.
Aeva Technologies, Inc. (NASDAQ:AEVA) designs and manufactures advanced LiDAR sensing systems and perception software, using Frequency Modulated Continuous Wave (FMCW) sensing.
6. Corcept Therapeutics Inc. (NASDAQ:CORT)
Market Cap: $7.2 Billion
Price Return over 1-Year: 100%
Potential Upside: 98%
Number of Hedge Fund Holders: 35
Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the best multibagger stocks to invest in right now. The company has recently revised its 2025 revenue guidance to $850–$900 million, down from the previous range of $900–$950 million. Despite the adjustment, management reiterated confidence in the company’s growth trajectory, pointing to contributions from an expanded sales force, new pharmacy partnerships, and progress in its pipeline.
CEO Joe Belinoff emphasized the potential of relacorilant, which has a December 30, 2025 PDUFA date. He projected that the drug could ultimately generate $3–$5 billion annually in hypercortisolism alone. Corcept Therapeutics Inc. (NASDAQ:CORT) has already established a dedicated oncology division to prepare for commercialization, with relacorilant plus nab-paclitaxel expected to launch quickly if approved.
Additional studies are underway in earlier cancer settings, other tumor types, and combination therapies, as well as in neurological and hepatic indications.
Operationally, pharmacy capacity limited Q2 revenue growth, but a second pharmacy is expected to come online by Q4, positioning the company for stronger momentum into 2026. A second pharmacy is being brought online, with financial impact expected in Q4, positioning the company for stronger momentum into 2026.
Corcept Therapeutics Inc.’s (NASDAQ:CORT) stock has doubled over the past year, and consensus still indicates another 100% return over the next 12 months. All analysts covering it have assigned it a Buy or equivalent rating.
Corcept Therapeutics Inc. (NASDAQ:CORT) is a commercial-stage company focused on the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders through modulation of hormone cortisol activity.
5. Microvast Holdings Inc. (NASDAQ:MVST)
Market Cap: $812 Million
Price Return over 1-Year: 837%
Potential Upside: 117%
Number of Hedge Fund Holders: 11
Microvast Holdings Inc. (NASDAQ:MVST) is one of the best multibagger stocks to invest in right now. The company is positioned to benefit from the global shift toward electrification, supported by rising EV adoption and favorable government policies. Microvast Holdings Inc. (NASDAQ:MVST) develops and manufactures advanced lithium-ion battery solutions tailored for electric vehicles and energy storage, two of the fastest-growing markets in the energy transition.
Its vertically integrated business model, covering raw materials through to battery pack assembly, provides meaningful cost efficiencies and performance differentiation compared to peers.
The company has an ambitious growth outlook and to meet increasing demand, the company is expanding its Huzhou facility, which will add about 2 gigawatt-hours of annual production capacity. For 2025, revenue is forecasted to rise 18% to 25%, reaching $450-$475 million. Profitability is also improving as management recently lifted its gross margin guidance to 32%, up from 30%, reflecting better operating leverage.
With scale expansion, margin improvement, and tailwinds from rising demand, Microvast Holdings Inc. (NASDAQ:MVST) represents a compelling growth story in next-generation energy storage.
Microvast Holdings Inc. (NASDAQ:MVST) is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions.
4. Trevi Therapeutics Inc. (NASDAQ:TRVI)
Market Cap: $848 Million
Price Return over 1-Year: 145%
Potential Upside: 185%
Number of Hedge Fund Holders: 34
Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now. On August 21, Morgan Stanley’s Judah Frommer initiated coverage of the stock with an Overweight rating and an $18 price target. The Overweight call is based on Haduvio, the company’s extended-release formulation of nalbuphine, which is being developed as a treatment for chronic cough.
Frommer said Haduvio stands out in a market where existing therapies either offer limited benefit or pose risks such as abuse and respiratory complications. He highlighted its potential to meet a large unmet need for patients with persistent cough.
The analyst estimates that Haduvio could become a multi-billion-dollar opportunity for Trevi Therapeutics Inc. (NASDAQ:TRVI), with growing interest in the pharmaceutical industry adding further support. Large-cap peers such as GSK and Merck have already committed to billion-dollar partnerships in the chronic cough space, suggesting Trevi Therapeutics Inc. (NASDAQ:TRVI) could benefit from heightened attention and investment.
Trevi Therapeutics Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company developing Haduvio to help patients suffering from chronic cough.
3. Compass Therapeutics Inc. (NASDAQ:CMPX)
Market Cap: $592 Million
Price Return over 1-Year: 119%
Potential Upside: 205%
Number of Hedge Fund Holders: 15
Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best multibagger stocks to invest in right now. The company’s lead program, CTX-009, is progressing through clinical trials for advanced solid tumors, particularly biliary tract cancer (BTC), where the company estimates a market opportunity exceeding $1 billion. Notably, Compass Therapeutics Inc. (NASDAQ:CMPX) is pointing out a significant unmet medical need, as around 85% of BTC patients who fail first-line therapy have no approved, effective treatment.
On that front, analyst Michael Schmidt of Guggenheim released an optimistic report. On August 12, the analyst raised his price target on Compass Therapeutics Inc. (NASDAQ:CMPX) to $12 from $10, and maintained a Buy rating. The call followed the release of Q2 results, which included encouraging pipeline updates and new clinical data.
Management updated guidance for the COMPANION-002 Phase 2/3 trial of tovecimig in biliary tract cancer. Final progression-free survival and overall survival data are now expected in early 2026, as opposed to the prior timeline of Q4 2025. While slightly later than planned, the trial remains on track and is viewed as a key near-term catalyst.
Schmidt cited stronger conviction in tovecimig and added probability-adjusted value from CTX-8371 as drivers of the higher target. Overall, the update reflects growing confidence in Compass Therapeutics Inc.’s (NASDAQ:CMPX) pipeline, which is beginning to show clearer signs of clinical and commercial potential.
Compass Therapeutics Inc. (NASDAQ:CMPX) is a clinical-stage biotechnology firm developing next-generation antibody therapies for cancer. Its lead programs, tovecimig and CTX-8371, target difficult-to-treat tumors.
2. Gossamer Bio Inc. (NASDAQ:GOSS)
Market Cap: $592 Million
Price Return over 1-Year: 192%
Potential Upside: 206%
Number of Hedge Fund Holders: 31
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best multibagger stocks to invest in right now. The company’s focus lies on its lead asset, Seralutinib, which targets pulmonary arterial hypertension (PAH), a severe condition with limited treatment options. Investor enthusiasm for the stock has grown markedly this year. It was trading around $1 at the start of the year and has since climbed to $2.50, delivering nearly 180% returns year-to-date.
In line with that performance, analyst sentiment has also strengthened. Gossamer Bio Inc. (NASDAQ:GOSS) received a Buy rating from Yasmeen Rahimi of Piper Sandler on September 5, with a price target of $15 reiterated.
The call comes shortly after H.C. Wainwright’s Patrick Trucchio reaffirmed his Buy rating on August 19 with a $10 target, highlighting confidence in the company’s lead candidate, seralutinib.
Trucchio’s report highlighted that the recent literature reviews and trial extensions have reinforced optimism around seralutinib. Data from the open-label extension of the Phase 2 study showed benefits held-up for 72 weeks, including reduced pulmonary vascular resistance and improved six-minute walk distance. These findings suggest the drug may have disease-modifying potential rather than offering only short-term relief.
He also pointed to the possibility of using seralutinib in combination with other therapies, which could broaden its role in pulmonary treatment. The upcoming Phase 3 PROSERA trial, with results expected in February 2026, remains the next major catalyst.
Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company developing therapies for pulmonary and cardiovascular diseases.
1. aTyr Pharma Inc. (NASDAQ:ATYR)
Market Cap: $523 Million
Price Return over 1-Year: 209%
Potential Upside: 245%
Number of Hedge Fund Holders: 16
aTyr Pharma Inc. (NASDAQ:ATYR) is one of the best multibagger stocks to invest in right now. On August 22, Leerink Partners’ Faisal Khurshid reiterated a Buy rating on aTyr Pharma Inc. (NASDAQ:ATYR) with a $16 price target. His view reflects optimism around the EFZO-FIT trial, which is testing efzofitimod as a potential treatment for pulmonary sarcoidosis.
Khurshid highlights that feedback from two MEDACorp key opinion leaders (KOLs) involved in the study suggests that efzofitimod could offer a safe, steroid-sparing option if the results prove favorable. He said that anecdotal cases of successful steroid tapering added to the confidence, even though the trial’s small size and blinded design limit visibility. Both KOLs highlighted the strength of patient selection and trial operations, which were structured to reduce placebo effects.
One of the KOLs had calculated the probability of success at 65-70%, slightly above Khurshid’s own 60% view. While the trial remains high-risk, Khurshid believes the potential reward justifies the Buy rating, given efzofitimod’s opportunity to address a serious unmet medical need.
aTyr Pharma Inc. (NASDAQ:ATYR) is a clinical-stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
While we acknowledge the potential of ATYR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ATYR and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Most Shorted Stocks Right Now and 10 Best High Beta Stocks To Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
